Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…Abstract Number: 0597 • ACR Convergence 2025
Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Background/Purpose: No studies have directly examined the link between 25-hydroxyvitamin D [25(OH)D] and cardiovascular outcomes in SLE. This study aimed to assess this association, hypothesizing…Abstract Number: 0265 • ACR Convergence 2025
Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
Background/Purpose: Patients with inflammatory arthritis (IA) have increased cardiovascular risk. Coronary artery calcium (CAC) scoring by computed tomography (CT) detects early coronary disease and structural…Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…Abstract Number: 1947 • ACR Convergence 2025
Coronary computed tomography incidental findings in rheumatoid arthritis.
Background/Purpose: Patients with rheumatoid arthritis (RA) have a greater cardiovascular risk than does the general population. The coronary calcium score is a measure used to…Abstract Number: 1528 • ACR Convergence 2025
Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…Abstract Number: 1112 • ACR Convergence 2025
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Background/Purpose: The cardiovascular risks associated with osteoporosis medications remain incompletely understood. Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular…Abstract Number: 0559 • ACR Convergence 2025
Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are associated with increased risk of cardiovascular (CV) disease driven by chronic systemic inflammation, with IL-17A…Abstract Number: 0249 • ACR Convergence 2025
Obesity as a possible confusion factor in the scleroderma pattern
Background/Purpose: The 2023 EULAR criteria for systemic sclerosis reaffirm the diagnostic value of nailfold videocapillaroscopy (NVC), particularly the presence of giant capillaries and capillary loss…Abstract Number: 2377 • ACR Convergence 2025
Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of mortality among patients with systemic lupus erythematosus (SLE). Statin medications play a crucial role for…Abstract Number: 1913 • ACR Convergence 2025
Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for autoimmune diseases but carries a risk of antimalarial-induced cardiomyopathy (AMIC) that increases with long-term use and is often…Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…Abstract Number: 0820 • ACR Convergence 2025
Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (JSLE). There is an urgent need to identify…Abstract Number: 0242 • ACR Convergence 2025
Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease (mediated by IL-1) that requires long-term treatment, and selection of therapy is guided by multiple factors.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 38
- Next Page »